SCHEMBL3486508

SCHEMBL3486508

OCCSc1nc(-c2ccccc2)c2cc(Cl)ccc2n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.74
▸ MAPK1 P28482 1/20 0.74
▸ MAPT P10636 7/20 0.67
▸ ALDH1A1 P00352 6/20 0.67
▸ TP53 P04637 3/20 0.67
▸ NPSR1 Q6W5P4 2/20 0.67
▸ HPGD P15428 1/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ USP2 O75604 2/20 0.52
▸ CASP1 P29466 2/20 0.52
▸ CASP7 P55210 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ GAA P10253 4/20 0.51
▸ MAT2A P31153 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ RAD52 P43351 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ LMNA P02545 1/20 0.49
▸ ADORA1 P30542 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101918 0.79 KDM4E (1.00) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL13585102 0.79 KDM4E (0.62) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL23269354 0.77 KDM4E (0.69) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL21641647 0.74 ALDH1A1 (0.86) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL24108921 0.74 MAPT (0.61) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL3488484 0.74 ALDH1A1 (1.00) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL3486575 0.74 KDM4E (0.71) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL13585302 0.72 MAPK1 (0.65) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL11807689 0.72 KDM4E (0.59) KDM4EMAPK1MAPTALDH1A1TP53
SCHEMBL8925803 0.71 HSP90AB1 (0.75) KDM4EMAPK1MAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100507-B1 QUINAZOLINE DERIVATIVES CAPABLE OF INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL CO (JP) 2015-02-25 — — EP disclosed
US-8722580-B2 Agent for inhibiting cytokinin signaling SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-05-13 — — US disclosed
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-04 — — US disclosed
CN-101588716-A Substance capable of inhibiting cytokinin signaling SUMITOMO CHEMICAL CO (JP) 2009-11-25 — — CN disclosed
EP-2100507-A1 SUBSTANCE CAPABLE OF INHIBITING CYTOKININ SIGNALING Sumitomo Chemical Company, Limited (JP) 2009-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING CROCC, STAT3, GRK6 KDM4E 4572/4885MAPK1 79/4885MAPT 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback